Indivior (INDV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Voting matters and shareholder proposals
Election of eight directors is proposed, with all nominees recommended for approval by the board.
Advisory vote on executive compensation is included, with board recommending approval.
Advisory vote on the preferred frequency of future say-on-pay votes is presented, with 'Year' as the recommended option.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026 is proposed.
Other business may be addressed as appropriate during the meeting or any adjournment.
Board of directors and corporate governance
Eight director nominees are listed for election at the annual meeting.
Executive compensation and say-on-pay
Advisory vote on named executive officer compensation is scheduled.
Shareholders are asked to indicate preferred frequency for future say-on-pay votes.
Latest events from Indivior
- Strong financial results, U.S. redomicile, and robust governance mark a pivotal year.INDV
Proxy filing27 Mar 2026 - Record SUBLOCADE growth, margin gains, and a $400M share repurchase program set up further acceleration.INDV
Q4 202526 Feb 2026 - SUBLOCADE drives strong revenue and EBITDA growth, with 2026 set for further acceleration.INDV
Investor presentation26 Feb 2026 - Q3 2024 revenue up 13% and profit up 62%, led by SUBLOCADE and strong U.S. sales.INDV
Q3 202416 Feb 2026 - Q1 2025 revenue fell 6% as generic competition intensified; cost controls supported profit.INDV
Q1 202516 Feb 2026 - FY 2024 guidance cut, PERSERIS discontinued, $85m litigation settled; long-term targets intact.INDV
Investor Update3 Feb 2026 - Q2 2024 revenue up 8%, SUBLOCADE up 24%, $75m litigation provision, $100m buyback.INDV
Q2 20243 Feb 2026 - Addiction treatment growth accelerates with new products, pipeline advances, and U.S. market focus.INDV
Jefferies Global Healthcare Conference31 Jan 2026 - OUD treatment growth continues amid easing Medicaid headwinds and focused pipeline development.INDV
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026